Long-Term Clinical Outcomes of Invasive Giant Prolactinomas after a Mean Ten-Year Followup.
Long-Term Clinical Outcomes of Invasive Giant Prolactinomas after a Mean Ten-Year Followup.
复制标题
平均十年随访后侵袭性巨型催乳素瘤的长期临床结果
DOI：
10.1155/2016/8580750
复制
发表时间：
2016
影响因子：
2.8
通讯作者：
Wu ZB
中科院分区：
文献类型：
--
作者：
Wu ZR;Zhang Y;Cai L;Lin SJ;Su ZP;Wei YX;Shang HB;Yang WL;Zhao WG;Wu ZB
Objective. The aim of this study is to observe clinical outcomes after more than ten years of followup in a group of patients with invasive giant prolactinomas (IGPs) treated with dopamine agonists (DAs). Methods. Twenty-five patients met the criteria of IGPs, among which 16 patients primarily received bromocriptine (BRC) and the other nine had undergone unsuccessful microsurgery prior to BRC treatment. Results. After a mean follow-up period of 135.5 ± 4.7 months, the clinical symptoms in all patients improved by different degrees. Tumor volume was decreased by a mean of 98.6%, and the tumors of 19 patients had almost completely disappeared. The mean duration of treatment at maximal doses of BRC was 48.5 months. At the last follow-up visit, nineteen patients had normal PRL levels, and 14 of these patients had received the low-dose BRC treatment (at an average of 2.9 ± 0.3 mg/d). Younger patients < 25 years had a significantly higher rate of persistent hyperprolactinemia after long-term BRC treatment (p = 0.043). Conclusion. DAs are a first-line therapy for IGPs because they can effectively achieve long-term control in both shrinking tumor volume and normalizing the PRL level, and majority of patients need low-dose DA maintenance. Younger patients are prone to persistent hyperprolactinemia despite long-term DA treatment.
登录
查看更多内容
影响因子：
5.8
作者：
Shimon, Ilan;Benbassat, Carlos;Hadani, Moshe
通讯作者：
Hadani, Moshe
影响因子：
--
作者：
BARRERA, CM;RUIZ, AE;BANKS, WA
通讯作者：
BANKS, WA
影响因子：
5.4
作者：
Berwaerts, J;Verhelst, J;Mahler, C
通讯作者：
Mahler, C
影响因子：
5.8
作者：
Colao, A;DiSarno, A;Lombardi, G
通讯作者：
Lombardi, G
影响因子：
3.2
作者：
Delgrange, E;Duprez, T;Maiter, D
通讯作者：
Maiter, D